ACS nano · 2025
An Intein-Spliced Nipah G Protein Ferritin Nanoparticle Vaccine Provides Complete Protection against Lethal Nipah Virus Challenge.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Shaohong, Zhang Xinghai, Yao Yanfeng, Chuai Xia, Li Kangyin, Zhang Baoyue, Ye Tianxi, Wu Yan, Ran Yong, Chen Li, Wang Shengdong, Wang Weiqi, Gong Rui, Zhang Huajun, Chiu Sandra
Аннотация
Nipah virus (NiV) is a serious hazard to human health since it can cause severe respiratory infections and viral encephalitis with a high fatality rate. Given the lack of a licensed NiV vaccine, there is an urgent need to develop one to protect public health. Previously, we developed NiV G protein nanoparticle vaccines by loading G protein onto ferritin nanoparticles (FeNP) via SpyCatcher/SpyTag technology, resulting in nanoparticles with three layers (FeNP-SC/ST-Ghead), including the inner core of ferritin (20 kDa), the intermediate layer of covalently linked SpyCatcher/SpyTag (11.2 kDa) and the outer layer of G protein. The intermediate layer is unnecessary in terms of immunization and occupies immune resources in the body. In this study, we used a split-intein to conjugate NiV Ghead onto FeNP, yielding FeNP-Ghead with two layers. In BALB/c mice, FeNP-Ghead could avoid immune response against SpyCatcher, elicit high levels of specific humoral immune responses for up to 217 days and long-lasting Th1-biased cellular immune responses. Furthermore, FeNP-Ghead showed potent protection efficacy in the hamster model, with immunization of 1 μg providing 100% protection against challenge with 1000 LD50 of NiV, and even as low as 0.2 μg being partially protective (83% survival). Since FeNP-Ghead has a lower protein content than FeNP-SC/ST-Ghead, it will occupy fewer immune resources in vivo, thereby reduce the potential for adverse immune side effect.